Business Context and Reporting Period
Company: Nektar Therapeutics (NKTR)
Filing Type: Form 8-K (Current Report)
Date: April 20, 2026
Subject: Announcement of 52-week topline results from the blinded 16-week treatment extension period of the REZOLVE-AA Phase 2b study for rezpegaldesleukin in patients with severe-to-very-severe alopecia areata (AA).
Key Financial Metrics
This filing is a Current Report on Form 8-K focused on clinical trial results and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Clinical Results
The filing details the 52-week outcomes of the REZOLVE-AA study involving 92 patients. Key clinical findings include:
- Study Design: Global study with a 36-week induction phase followed by a blinded 16-week treatment extension for eligible patients (SALT Score >20 with hair growth).
- Extension Cohort: 31 patients continued into the extension (27 on rezpegaldesleukin, 4 on placebo).
- Week 52 Efficacy (Overall Population):
- SALT Score ≤20 (≥80% scalp coverage): 25.8% (low dose) and 27.6% (high dose) vs. 6.7% (placebo); p-value 0.049.
- SALT Score ≤30 (≥70% scalp coverage): 30.2% (low dose) and 35.0% (high dose) vs. 8.4% (placebo); p-value 0.023.
- SALT 50 (≥50% improvement): 37.7% (low dose) and 38.8% (high dose) vs. 13.6% (placebo).
- SALT 30 (≥30% improvement): 45.6% (low dose) and 47.6% (high dose) vs. 24.2% (placebo).
- Extension Period Response: From week 36 to 52, 29% (low dose) and 31% (high dose) achieved new SALT Score ≤20 responses, compared to none in the placebo arm.
- Safety: Favorable profile observed over 52 weeks. 94% of extension patients completed treatment. No discontinuations due to treatment-emergent adverse events (TEAEs). Most common TEAEs were mild-to-moderate injection site reactions.
Guidance, Outlook, and Risks
Outlook: The Company plans to submit the REZOLVE-AA results for presentation at a medical conference in 2026.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks include:
- Rezpegaldesleukin remains an investigational agent with a high risk of failure prior to regulatory approval.
- Future clinical studies may yield negative safety or efficacy findings despite positive earlier results.
- Potential delays in clinical trial timelines due to regulatory issues, enrollment, manufacturing, or changing standards of care.
- Fast Track designation does not guarantee marketing approval.
Investor Verification Checklist
- Verify the statistical significance and clinical relevance of the SALT Score improvements in the context of the broader alopecia areata treatment landscape.
- Confirm the timeline and venue for the upcoming medical conference presentation of these results.
- Review the full safety data regarding injection site reactions and long-term tolerability in the attached press release (Exhibit 99.1) and presentation (Exhibit 99.2).
- Assess the Company's cash runway and capital requirements for advancing rezpegaldesleukin to Phase 3, as this filing does not provide financial status.
- Monitor for any updates on regulatory interactions or Fast Track designation status following the data release.